ScholarIQanswers from OpenAlex
Virus-based gene therapy research
TopicLeading institutions, researchers & key papers
Virus-based gene therapy research is a topic indexed in ScholarIQ from OpenAlex.
What is known about Virus-based gene therapy research?
ScholarIQrecord summary
This cluster of papers covers a wide range of topics related to gene therapy, including the use of viral vectors such as AAV and adenovirus, advancements in oncolytic virus therapy, hematopoietic stem cell gene therapy, immunodeficiency treatments, lentiviral vector applications, transgene expression, and genomic integration. The research reflects the ongoing progress and challenges in the field of gene therapy.
How many works does Virus-based gene therapy research have?
ScholarIQindexed works
Virus-based gene therapy research has 255 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Virus-based gene therapy research?
ScholarIQopenalex
The OpenAlex for Virus-based gene therapy research is on the source record.
What are the most-cited papers on Virus-based gene therapy research?
ScholarIQmost cited works
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response
Catherine S. Manno, Glenn F. Pierce, Valder R. Arruda, Bertil Glader, Margaret V. Ragni, John E.J. Rasko, Margareth C. Ozelo, Keith Hoots, Philip M. Blatt, Barbara A. Konkle, Michael D. Dake, Robin Kaye, Mahmood Razavi, Albert Zajko, James L. Zehnder, Pradip K. Rustagi, Hiroyuki Nakai, Amy Chew, Debra G. B. Leonard, J Fraser Wright, Ruth Lessard, Jürg M. Sommer, Michael Tigges, Denise E. Sabatino, Alvin Luk, Haiyan Jiang, Federico Mingozzi, Linda Couto, Hildegund C.J. Ertl, Katherine A. High, Mark A. Kay
In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors
Kenneth W. Culver, Zvi Ram, Stuart Wallbridge, Hiroyuki Ishii, Edward H. Oldfield, R. Michael Blaese
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Fengcai Zhu, Yu-Hua Li, Xu-Hua Guan, Li-Hua Hou, Wen-Juan Wang, Wen-Juan Wang, J X Li, Shi-Po Wu, Zhao Wang, Lei Wang, Lei Wang, Hu-Dachuan Jiang, Hu-Dachuan Jiang, Ling Wang, T Jiang, Yu Hu, Jin-Bo Gou, Junjie Xu, Junjie Xu, Wei Wang, Wei Chen, Wei Wang, Wei Chen
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Fengcai Zhu, Xu-Hua Guan, Yu-Hua Li, Jian-Ying Huang, Tao Jiang, Li-Hua Hou, Jingxin Li, Bei-Fang Yang, Ling Wang, Wen-Juan Wang, Shi-Po Wu, Zhao Wang, Xiao-Hong Wu, Junjie Xu, Zhe Zhang, Si-Yue Jia, Busen Wang, Yi Hu, Jing‐Jing Liu, Jun Zhang, Xiao-Ai Qian, Qiong Li, Hong-Xing Pan, Hu-Dachuan Jiang, Peng Deng, Jin-Bo Gou, Xue-Wen Wang, Xue-Wen Wang, Xinghuan Wang, Xinghuan Wang, Wei Chen
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Guangping Gao, Luk H. Vandenberghe, Mauricio R. Alvira, You Lü, Roberto Calcedo, Xiangyang Zhou, James M. Wilson
Where is Virus-based gene therapy research research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Virus-based gene therapy research is open access?
ScholarIQopen access share
60%OPEN ACCESS